PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1371890
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1371890
Antimicrobial Resistance Diagnostic Market Forecasts to 2030 - Global Analysis By Pathogen, Technology, End User and By Geography
According to Stratistics MRC, the Global Antimicrobial Resistance Diagnostic Market is accounted for $4.76 billion in 2023 and is expected to reach $9.58 billion by 2030 growing at a CAGR of 10.5% during the forecast period. The market for diagnostic tests and instruments used to find and establish the presence of antimicrobial resistance (AMR) in microorganisms is referred to as the "antimicrobial resistance diagnostic market." As a result of the development of the ability of microorganisms, including bacteria, viruses, fungi, and parasites, to withstand the effects of antimicrobial medications, which reduces or eliminates their effectiveness in treating infections, antimicrobial resistance is a major public health concern worldwide.
According to the United States Pharmacopeial Convention, AMR caused about 700,000 deaths globally every year. Moreover, the number can reach 10 million each year by 2050, if diagnosis and treatment of microbial infections are not managed properly.
Market Dynamics:
Driver:
Increasing initiatives and awareness
Increased initiatives aimed at combating the problem were made possible by the growing knowledge of the effects of antibiotic resistance among healthcare professionals, legislators, and the general public. Furthermore, governments, organizations, and regulatory authorities have started campaigns to encourage the responsible use of antibiotics as well as the creation and acceptance of diagnostic tools to combat resistance.
Restraint:
Expensive diagnostic procedures and policies for limited reimbursement
Some cutting-edge antimicrobial resistance diagnostic tests can be expensive, which restricts access to and use of them, particularly in places with low resources. The high price of diagnostic tests may be an obstacle to market expansion, especially in areas with constrained healthcare resources. However, antimicrobial resistance diagnostics may be covered and reimbursed under different policies, depending on the region and healthcare system. Their uptake and market expansion may be hampered by inadequate payment or a lack of insurance coverage for certain tests.
Opportunity:
Technological developments and guidelines and support for regulations
Diagnostic technology advancements in areas like molecular diagnostics and next-generation sequencing have improved the capability of tests for antibiotic resistance. These innovations allow for the quicker and more precise detection of resistance markers, empowering medical professionals to determine effective treatments. Additionally, the importance of antibiotic resistance has been acknowledged by regulatory bodies and healthcare organizations, which have released recommendations and guidelines to promote their usage. These regulations support the regulatory environment needed for market expansion while facilitating the uptake of diagnostics.
Threat:
Inadequate infrastructure and expertise and complex regulatory procedures
Antimicrobial resistance tests may not be used to their full potential in some areas due to a lack of knowledge about them. Inadequate healthcare infrastructure and a lack of laboratory space might also prevent the use of modern diagnostics and restrain market expansion. However, it might take a while and be difficult to get regulatory approval for novel diagnostic tests for antibiotic resistance. The introduction of novel diagnostics might be hampered by strict regulatory regulations, which can often delay the launch of products.
COVID-19 Impact:
Priorities in healthcare have dramatically changed as a result of the COVID-19 pandemic to focus on managing and containing the virus's spread. Resources have been redirected toward COVID-19 testing and treatment, including laboratory capacity and manpower. The concentration on antimicrobial resistance diagnostics and research efforts in this area may have been momentarily hampered by this resource relocation. Due to the possibility of secondary bacterial infections in COVID-19 patients, the COVID-19 pandemic has resulted in an increase in the use of antibiotics.
The methicillin resistant staphylococcus aureus segment is expected to be the largest during the forecast period
Methicillin Resistant Staphylococcus Aureus segment commanded the largest share over the forecast period. The main cause of the segment's growth is the rising prevalence of MRSA in hospital settings. For instance, the CDC reports that approximately two in every 100 of those with S. aureus on their noses develop MRSA. This percentage of the population is roughly 33%. Moreover, another element influencing the segment's growth is the rise in regulatory approvals for diagnostic tests for identifying MRSA.
The hospitals segment is expected to have the highest CAGR during the forecast period
Because of the rising rate of hospital-acquired infections, the surge in hospitalizations caused by the high rate of AMR infections, prolonged hospital stays, expanding access to cutting-edge diagnostic technologies, affordability, and better healthcare coverage, the hospital segment is predicted to grow profitably over the forecast period. Additionally, pathogenic infections, including MRSA, CDI, and DRSP, can result in pneumonia, sepsis, bloodstream infections, and surgical site infections. Therefore, the prevalence of pathogen-focused illnesses in hospitals also contributes to segment growth.
Region with largest share:
Due to the high risk of developing AMR, the presence of supportive government AMR regulations, and the region's advanced healthcare infrastructure, North America held the largest percentage over the predicted period. Furthermore, it is anticipated that regional expansion will be fueled in the upcoming years by the existence of major market participants and the strategic initiatives.
Region with highest CAGR:
During the forecast period, Asia-Pacific is expected to experience the most rapid expansion. A high frequency of antibiotic resistance, an increase in the demand for affordable diagnostic solutions, and the presence of unexplored market potential all contribute to the region's growth. Additionally, the region's expansion is also anticipated to be aided by the region's sizable, targeted population, growing geriatric population, and a number of government-sponsored awareness campaigns. Additionally, it is anticipated that growth in R&D efforts connected to the creation of improved diagnostic solutions will support region expansion.
Key players in the market:
Some of the key players in Antimicrobial Resistance Diagnostic market include: Abbott Laboratories, Accelerate Diagnostics, Inc., Becton, Dickinson and Company, Biomerieux , Danaher Corporation, F. Hoffmann-La Roche Ltd., Hologic, Inc., Molsid , OpGen, Vela Diagnostics and Visby Medical, Inc..
Key Developments:
In November 2022, Danaher Corporation came into partnership with Duke University, a research University. Under this partnership, Danaher Corporation aimed to shape Danaher Beacon for the development of Gene Therapy Innovation.
In August 2022, Becton, Dickinson, and Company entered into collaboration with Accelerate Diagnostics, Inc., a developer of rapid in-vitro diagnostics in microbiology. This Collaboration would enable the former company to help clinicians treat patients in a Constructive and organized way resulting in a decrease in costs in healthcare and helping restrict the stretch of antimicrobial resistance.
Pathogens Covered:
- Drug Resistant Streptococcus
- Drug Resistant Streptococcus Pneumoniae (DRSP)
- Methicillin Resistant Staphylococcus Aureus
- Clostridium Difficile (CD)
- Drug Resistant Neisseria Gonorrhoeae (DRNG)
- Drug Resistant Salmonella (DRNTS)
- Other Pathogens
Technologies Covered:
- Immunoassay
- Microbiology Culture
- Mass Spectrometry
- Rapid & Point of Care
- Other Technologies
End Users Covered:
- Pharmaceutical & Biotechnology Companies
- Diagnostic Laboratories
- Hospitals
- Other End Users
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Technology Analysis
- 3.7 End User Analysis
- 3.8 Emerging Markets
- 3.9 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Antimicrobial Resistance Diagnostic Market, By Pathogen
- 5.1 Introduction
- 5.2 Drug Resistant Streptococcus
- 5.3 Drug Resistant Streptococcus Pneumoniae (DRSP)
- 5.4 Methicillin Resistant Staphylococcus Aureus
- 5.5 Clostridium Difficile (CD)
- 5.6 Drug Resistant Neisseria Gonorrhoeae (DRNG)
- 5.7 Drug Resistant Salmonella (DRNTS)
- 5.8 Other Pathogens
6 Global Antimicrobial Resistance Diagnostic Market, By Technology
- 6.1 Introduction
- 6.2 Immunoassay
- 6.3 Microbiology Culture
- 6.4 Mass Spectrometry
- 6.5 Rapid & Point of Care
- 6.6 Other Technologies
7 Global Antimicrobial Resistance Diagnostic Market, By End User
- 7.1 Introduction
- 7.2 Pharmaceutical & Biotechnology Companies
- 7.3 Diagnostic Laboratories
- 7.4 Hospitals
- 7.5 Other End Users
8 Global Antimicrobial Resistance Diagnostic Market, By Geography
- 8.1 Introduction
- 8.2 North America
- 8.2.1 US
- 8.2.2 Canada
- 8.2.3 Mexico
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 Italy
- 8.3.4 France
- 8.3.5 Spain
- 8.3.6 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 New Zealand
- 8.4.6 South Korea
- 8.4.7 Rest of Asia Pacific
- 8.5 South America
- 8.5.1 Argentina
- 8.5.2 Brazil
- 8.5.3 Chile
- 8.5.4 Rest of South America
- 8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 UAE
- 8.6.3 Qatar
- 8.6.4 South Africa
- 8.6.5 Rest of Middle East & Africa
9 Key Developments
- 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 9.2 Acquisitions & Mergers
- 9.3 New Product Launch
- 9.4 Expansions
- 9.5 Other Key Strategies
10 Company Profiling
- 10.1 Abbott Laboratories
- 10.2 Accelerate Diagnostics, Inc.
- 10.3 Becton, Dickinson and Company
- 10.4 Biomerieux
- 10.5 Danaher Corporation
- 10.6 F. Hoffmann-La Roche Ltd.
- 10.7 Hologic, Inc.
- 10.8 Molsid
- 10.9 OpGen
- 10.10 Vela Diagnostics
- 10.11 Visby Medical, Inc.
List of Tables
- Table 1 Global Antimicrobial Resistance Diagnostic Market Outlook, By Region (2021-2030) ($MN)
- Table 2 Global Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
- Table 3 Global Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
- Table 4 Global Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
- Table 5 Global Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
- Table 6 Global Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
- Table 7 Global Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
- Table 8 Global Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
- Table 9 Global Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
- Table 10 Global Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
- Table 11 Global Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
- Table 12 Global Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
- Table 13 Global Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
- Table 14 Global Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
- Table 15 Global Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
- Table 16 Global Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
- Table 17 Global Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
- Table 18 Global Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
- Table 19 Global Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 20 Global Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 21 North America Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
- Table 22 North America Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
- Table 23 North America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
- Table 24 North America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
- Table 25 North America Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
- Table 26 North America Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
- Table 27 North America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
- Table 28 North America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
- Table 29 North America Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
- Table 30 North America Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
- Table 31 North America Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
- Table 32 North America Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
- Table 33 North America Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
- Table 34 North America Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
- Table 35 North America Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
- Table 36 North America Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
- Table 37 North America Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
- Table 38 North America Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
- Table 39 North America Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 40 North America Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 41 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
- Table 42 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
- Table 43 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
- Table 44 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
- Table 45 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
- Table 46 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
- Table 47 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
- Table 48 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
- Table 49 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
- Table 50 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
- Table 51 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
- Table 52 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
- Table 53 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
- Table 54 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
- Table 55 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
- Table 56 Europe Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
- Table 57 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
- Table 58 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
- Table 59 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 60 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 61 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
- Table 62 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
- Table 63 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
- Table 64 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
- Table 65 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
- Table 66 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
- Table 67 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
- Table 68 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
- Table 69 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
- Table 70 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
- Table 71 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
- Table 72 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
- Table 73 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
- Table 74 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
- Table 75 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
- Table 76 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
- Table 77 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
- Table 78 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
- Table 79 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 80 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 81 South America Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
- Table 82 South America Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
- Table 83 South America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
- Table 84 South America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
- Table 85 South America Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
- Table 86 South America Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
- Table 87 South America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
- Table 88 South America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
- Table 89 South America Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
- Table 90 South America Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
- Table 91 South America Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
- Table 92 South America Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
- Table 93 South America Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
- Table 94 South America Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
- Table 95 South America Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
- Table 96 South America Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
- Table 97 South America Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
- Table 98 South America Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
- Table 99 South America Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 100 South America Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 101 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
- Table 102 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
- Table 103 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
- Table 104 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
- Table 105 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
- Table 106 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
- Table 107 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
- Table 108 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
- Table 109 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
- Table 110 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
- Table 111 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
- Table 112 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
- Table 113 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
- Table 114 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
- Table 115 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
- Table 116 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
- Table 117 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
- Table 118 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
- Table 119 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 120 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
